New study tests rinvoq for psoriatic arthritis spine pain
NCT ID NCT06454188
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether upadacitinib (Rinvoq), a daily pill, can reduce inflammation in the spine and joints of people with active psoriatic arthritis. About 100 adults who have not responded well to other treatments will receive either the drug or a placebo for 12 weeks. Researchers will use MRI scans and symptom scores to measure changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib (Rinvoq)
What this could lead to
If successful, this could show that upadacitinib effectively reduces spinal and joint inflammation in people with psoriatic arthritis, offering a new treatment option.
What could go wrong
This is a phase 4 trial with only 100 participants, so results may not apply to everyone. Upadacitinib can have side effects like infections, and the placebo group may also show improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Groupe de Recherche en Maladies Osseuses (G.R.M.O.) Inc.
RECRUITINGQuébec, Quebec, G1V 3M7, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, K1H 7W9, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••